38.58  -1.34 (-3.36%)		09-03 16:00
Open: 40.24 High: 40.5 Volume: 174,639		Pre. Close: 39.92 Low: 38.2 Market Cap: 1,564(M)

Short term
Mid term
Targets	6-month :	47.47	1-year :	55.45
Resists	First :	40.65	Second :	47.47
Pivot price	36.43
Supports	First :	35.84	Second :	32.88
MAs	MA(5) :	38.45	MA(20) :	35.84
	MA(100) :	37.62	MA(250) :	41.39
MACD	MACD :	1	Signal :	0.6
%K %D	K(14,3) :	80.9	D(3) :	79.8
RSI	RSI(14): 64
52-week	High :	59.82	Low :	28.13

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.
[ PAHC ] has closed below upper band by 16.6%. Bollinger Bands are 26.5% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

If tomorrow:	Open lower	Open higher
High:	40.53 - 40.74	40.74 - 40.87
Low:	37.73 - 37.99	37.99 - 38.16
Close:	38.2 - 38.6	38.6 - 38.85

Phibro Animal Health Corporation operates as a global entity focused on the research, production, and supply of a wide array of animal health and mineral nutrition solutions. While serving a global clientele, its primary market for livestock products is the United States. The company's operations are divided into three main business segments: Animal Health, Mineral Nutrition, and Performance Products. Phibro develops, manufactures, and markets products tailored for various food-producing animals, including poultry, swine, beef and dairy cattle, and aquaculture. Its Animal Health offerings encompass a broad range of pharmaceutical and biological products. These include antimicrobials (both chemical and biological agents) designed to prevent and treat bacterial ailments; anticoccidials, primarily used to control and prevent coccidiosis in poultry and cattle; anthelmintics for combating parasitic intestinal worm infestations; and specific anti-bloat treatments for cattle grazing on legume or wheat pastures. Additionally, the company provides specialized nutritional supplements engineered to enhance animal health and performance, alongside vaccines predominantly for the poultry and swine industries to protect against diseases. The Mineral Nutrition segment focuses on the creation and distribution of various trace mineral formulations and concentrates, featuring elements such as zinc, manganese, copper, iron, and other vital compounds. Furthermore, under its Performance Products segment, Phibro supplies an assortment of specialty ingredients that find application in diverse industries, including personal care, industrial chemicals, and chemical catalysts. Phibro's animal health and mineral nutrition products reach customers through a multi-channel distribution network, including its own local sales offices, direct sales to integrated poultry, swine, and cattle operations, and through commercial animal feed producers, wholesalers, and distributors. The company boasts an extensive international presence, conducting business across the United States, Latin America, Canada, Europe, the Middle East, Africa, and the Asia Pacific region. Initially known as Philipp Brothers Chemicals, Inc., the company adopted the name Phibro Animal Health Corporation in July 2003. It was officially incorporated in 2014 and maintains its corporate headquarters in Teaneck, New Jersey.

Wed, 02 Sep 2026
Phibro Animal Health Corp (PAHC) Shares Surge 3.9% -- What GF Sc - GuruFocus

Wed, 02 Sep 2026
Should Value Investors Buy Phibro Animal Health (PAHC) Stock? - Yahoo Finance

Mon, 31 Aug 2026
Phibro Animal Health Reports Significant Growth in Fiscal Year 2026 - Intellectia AI

Sun, 30 Aug 2026
Phibro Animal Health: Zoetis Integrated And Better Cash Flow Ahead (NASDAQ:PAHC) - Seeking Alpha

Thu, 27 Aug 2026
Phibro Animal Health (PAHC) Stock Shrugs Off Record Revenue As Margins Tighten - simplywall.st

Thu, 27 Aug 2026
Phibro Animal Health Q4 2026 Earnings Call: Complete Transcript - Sahm

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Underperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Underperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Outperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Outperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: NASDAQ
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Shares Out	21 (M)
Shares Float	21 (M)
Held by Insiders	0.8 (%)
Held by Institutions	103.6 (%)
Shares Short	1,190 (K)
Shares Short P.Month	1,220 (K)

EPS	2.32
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	8.92
Profit Margin	6.3 %
Operating Margin	12.5 %
Return on Assets (ttm)	8.3 %
Return on Equity (ttm)	30.3 %
Qtrly Rev. Growth	10.3 %
Gross Profit (p.s.)	23.19
Sales Per Share	71.19
EBITDA (p.s.)	11.14
Qtrly Earnings Growth	15.6 %
Operating Cash Flow	66 (M)
Levered Free Cash Flow	-18 (M)

PE Ratio	16.55
PEG Ratio	1.6
Price to Book value	4.32
Price to Sales	0.54
Price to Cash Flow	12.29

Dividend	0.11
Forward Dividend	0
Dividend Yield	0.3%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.